Evidence map›Paper›PMID 35915124›Full record

ArticleScientific reports2022

Prevalence of HPV-DNA and E6 mRNA in lung cancer of HIV-infected patients.

Guillem Sirera, Sebastián Videla, Verónica Saludes, Eva Castellà, Carolina Sanz, Aurelio Ariza, Bonaventura Clotet, Elisa Martró

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Guillem Sirera *Fight AIDS Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain.
Sebastián Videla *Fight AIDS Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain.
Verónica SaludesMicrobiology Department, Laboratori Clinic Metropolitana Nord, Germans Trias i Pujol University Hospital, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
Eva CastellàDepartment of Pathology, Germans Trias i Pujol University Hospital, Badalona, Spain.
Carolina SanzDepartment of Pathology, Germans Trias i Pujol University Hospital, Badalona, Spain.
Aurelio ArizaDepartment of Pathology, Germans Trias i Pujol University Hospital, Badalona, Spain.
Bonaventura ClotetFight AIDS Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain.
Elisa MartróMicrobiology Department, Laboratori Clinic Metropolitana Nord, Germans Trias i Pujol University Hospital, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. emartro@igtp.cat.
Hospital Universitari Germans Trias i Pujol · ESFundació Lluita contra les Infeccions · ESInstitut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ESUniversitat de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HIV-infected individuals could be at a greater risk for developing lung cancer than the general population due to the higher prevalence in the former of human papillomavirus (HPV) in the oral cavity and higher smoking rates. Our aim was to assess HPV prevalence and E6 viral oncogene transcription in lung cancer samples from HIV-infected individuals. This was a single-center, retrospective study of a cohort of HIV-1-infected patients diagnosed with and treated for lung cancer. Pathological lung samples archived as smears or formalin-fixed paraffin-embedded blocks were subjected to HPV genotyping, detection of human p16 protein and assessment for HPV E6 mRNA expression. Lung cancer samples from 41 patients were studied, including squamous cell carcinoma (32%), adenocarcinoma (34%), non-small cell cancer (27%), and small cell cancer (7%). HPV DNA was detected in 23 out of 41 (56%, 95% CI 41-70%) of samples and high-risk (HR)-HPV types were detected in 16 out of 41 (39%, 95% CI 26-54%), HPV-16 being the most prevalent [13/16 (81.3%, 95% CI 57.0-93%]. In samples with sufficient material left: expression of p16 was detected in 3 out of 10 (30%) of HR-HPV DNA-positive tumors and in 3 out of 7 (43%) of the negative ones; and E6 mRNA was detected in 2 out of 10 (20%) of HPV-16-positive samples (squamous lung cancers). These two patients had a background of a previous HPV-related neoplasia and smoking. HR-HPV DNA detection was prevalent in lung cancers in HIV-infected patients. However, viral oncogene expression was limited to patients with previous HPV-related cancers.

Indexed as

AlphapapillomavirusHIV InfectionsLung NeoplasmsOncogene Proteins, ViralPapillomavirus InfectionsDNA, ViralHumansPapillomaviridaePrevalenceRetrospective StudiesRNA, MessengerDNA, ViralOncogene Proteins, ViralRNA, Messenger

Identifiers

PMID35915124
PMCPMC9343353
OpenAlexW4289261753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.